ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
AstraZeneca’s MedImmune unit will collaborate with Advaxis, a U.S.-based specialist in developing cancer immunotherapies. The pair plans Phase I and II trials that combine MedImmune’s MEDI4736, an anti-PD-L1 immune checkpoint inhibitor, with Advaxis’s ADXS-HPV vaccine as a treatment for patients with certain cervical, head, and neck cancers associated with human papillomavirus. Advaxis will fund and conduct the study. MedImmune has first right of negotiation for further development of combinations involving MEDI4736 and ADXS-HPV.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X